The Lyrica dispute shows why a national stock total cannot answer whether a patient can obtain a specific medicine at a local pharmacy. Health Minister Alexandru Rogobete said that distributors and community pharmacies held 2,352,445 units of pregabalin medicines on 13 November. Journalist Liliana Ruse said she still could not buy a box in Bucharest. Those accounts need not conflict because they measure different things.
In a Facebook post, Rogobete said the total covered branded Lyrica and generic versions. He put combined distributor and community-pharmacy stocks of 75mg, 150mg and 300mg Lyrica at 645,834 units. He also said a particular medicine might not be immediately available at a particular pharmacy. That supports a limited conclusion: recorded stock exists somewhere in the national supply chain. It does not show that a given strength is available in a given area or can be dispensed without delay.
Ruse had said Lyrica and generic alternatives were difficult to find, adding that the medicine helps her manage neuropathy after chemotherapy. After the minister's response, she said she would pay for him to buy her a box in Bucharest. HotNews did not provide independently checked pharmacy inventories, the duration of any local unavailability, or regional distribution data. The report therefore cannot establish the scale of a shortage or assign responsibility to a particular point in the supply chain.
That is also the weakness of a response built only around an aggregate figure. Patients do not collect medicine from a national total; they need a prescribed strength at a particular place. If the government wants stock data to answer availability concerns, it should publish usable detail on regional distribution, strengths, retail availability and update frequency. National stock can be real while still failing to answer whether a patient can obtain the medicine needed today.
Sources
- HotNews · Source date: 2026-11-15
Independent editorial content. WUA is not affiliated with any political party. 2026-11-15
Rogobete’s warehouse-stock plan: What it could change in Romania’s medicine shortages